Carregant...
Distinct ET(A) Receptor Binding Mode of Macitentan As Determined by Site Directed Mutagenesis
The competitive endothelin receptor antagonists (ERA) bosentan and ambrisentan, which have long been approved for the treatment of pulmonary arterial hypertension, are characterized by very short (1 min) occupancy half-lives at the ET(A) receptor. The novel ERA macitentan, displays a 20-fold increas...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Public Library of Science
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4166607/ https://ncbi.nlm.nih.gov/pubmed/25226600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0107809 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|